First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Hye Ryun KimShunichi SugawaraJong-Seok LeeJin-Hyoung KangNaoki InuiToyoaki HidaKi Hyeong LeeTatsuya YoshidaHiroshi TanakaCheng-Ta YangMakoto NishioYuichiro OheTomohide TamuraNobuyuki YamamotoChong-Jen YuHiroaki AkamatsuShigeru TakahashiKazuhiko NakagawaPublished in: Cancer medicine (2023)
Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination. We believe this regimen is viable as a standard, first-line treatment for patients with advanced nsNSCLC without driver mutations in ALK, EGFR, or ROS1.
Keyphrases
- randomized controlled trial
- metastatic colorectal cancer
- small cell lung cancer
- study protocol
- epidermal growth factor receptor
- phase iii
- high grade
- tyrosine kinase
- dna damage
- locally advanced
- phase ii study
- cell death
- advanced non small cell lung cancer
- low grade
- chemotherapy induced
- reactive oxygen species
- double blind
- clinical trial
- squamous cell carcinoma